Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.87 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.87 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.87 |
| ▸ | PGR | P06401 | 1/20 | 0.87 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.87 |
| ▸ | F7 | P08709 | 4/20 | 0.65 |
| ▸ | F3 | P13726 | 4/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.65 |
| ▸ | PPARG | P37231 | 3/20 | 0.65 |
| ▸ | PPARD | Q03181 | 3/20 | 0.65 |
| ▸ | PPARA | Q07869 | 3/20 | 0.65 |
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12654675 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL122342 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL31398205 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL28523361 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL4814472 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL14458380 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL12654374 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL4814473 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL21670445 | 0.98 | ALDH1A1 (0.97) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 | |
| SCHEMBL21670446 | 0.98 | ALDH1A1 (0.97) | ALDH1A1CYP3A4ALOX15HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12440466-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | BASF AS (NO) | 2025-10-14 | — | — | US | disclosed |
| EP-4619001-A1 | ORAL DOSAGE FORMS FOR THE TREATMENT OF LIVER DISORDERS AND METHODS OF PREPARING THE SAME | Viking Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4479062-A1 | FORMES POSOLOGIQUES ORALES DE L'AGONISTE DE TRß, VK2809, POUR LE TRAITEMENT DE TROUBLES HÉPATIQUES, ET PROCÉDÉS DE PRÉPARATION DE CELLES-CI | Viking Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| EP-3720431-B1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2024-10-30 | — | — | EP | disclosed |
| US-20240293385-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | GANNEX PHARMA CO., LTD. (CN) | 2024-09-05 | — | — | US | disclosed |
| WO-2024107862-A1 | ORAL DOSAGE FORMS FOR THE TREATMENT OF LIVER DISORDERS AND METHODS OF PREPARING THE SAME | VIKING THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240156769-A1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2024-05-16 | — | — | US | disclosed |
| US-11925614-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | BASF AS (NO) | 2024-03-12 | — | — | US | disclosed |
| WO-2023158616-A1 | ORAL DOSAGE FORMS OF TRβ AGONIST VK2809 FOR THE TREATMENT OF LIVER DISORDERS AND METHODS OF PREPARING THE SAME | VIKING THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| CN-116033826-A | Method for improving the rain resistance of beneficial microorganisms | 罗地亚经营管理公司 | 2023-04-28 | — | — | CN | disclosed |
| US-20100160261-A1 | POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF | SCF PHARMA INC. (CA) | 2010-06-24 | — | — | US | disclosed |
| US-20100160261-A1 | POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF | SCF PHARMA INC. (CA) | 2010-06-24 | — | — | US | disclosed |
| US-20100035990-A1 | ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR) | PRONOVA BIOPHARMA NORGE AS (NO) | 2010-02-11 | — | — | US | disclosed |
| US-20090291102-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | SCF PHARMA INC. (CA) | 2009-11-26 | — | — | US | disclosed |
| US-20090292019-A1 | POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF | SCF PHARMA INC. (CA) | 2009-11-26 | — | — | US | disclosed |
| US-20090292019-A1 | POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF | SCF PHARMA INC. (CA) | 2009-11-26 | — | — | US | disclosed |
| US-20090291102-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | SCF PHARMA INC. (CA) | 2009-11-26 | — | — | US | disclosed |
| WO-2008113177-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008098375-A1 | POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF | CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINES (CA) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008053331-A1 | ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR). | PRONOVA BIOPHARMA NORGE A/S (SE) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035990-A1 | ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR) | PPARG, PPARA, FFAR3 | ALDH1A1 1088/4885CYP3A4 1014/4885ALOX15 53/4885 |
| US-20240156769-A1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | CPT1A, NR1H2, NR1H3 | ALDH1A1 154/4885CYP3A4 772/4885ALOX15 66/4885 |
| US-20090292019-A1 | POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF | FASN, MGLL, FADS1 | ALDH1A1 695/4885CYP3A4 4044/4885ALOX15 34/4885 |
| US-12440466-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | CPT1A, NR1H2, NR1H3 | ALDH1A1 154/4885CYP3A4 772/4885ALOX15 66/4885 |
| US-20090291102-A1 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF | MGLL, PNLIP, FASN | ALDH1A1 1033/4885CYP3A4 1541/4885ALOX15 17/4885 |
| US-11925614-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | CPT1A, NR1H3, NR1H2 | ALDH1A1 162/4885CYP3A4 796/4885ALOX15 65/4885 |
| US-20100160261-A1 | POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF | FASN, MGLL, FADS1 | ALDH1A1 695/4885CYP3A4 4044/4885ALOX15 34/4885 |
| US-20240293385-A1 | COMBINATION THERAPY FOR TREATMENT OF LIVER DISEASES | SLC10A1, OAT, GOT2 | ALDH1A1 406/4885CYP3A4 420/4885ALOX15 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.